Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
This study has been completed.
Study NCT00033605 Information provided by National Cancer Institute (NCI)
First Received on April 9, 2002. Last Updated on September 2, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cervical Cancer
Colorectal Cancer
Diarrhea
Endometrial Cancer
Fallopian Tube Cancer
Ovarian Cancer
Prostate Cancer
Sarcoma
Vaginal Cancer
Vulvar Cancer
Additional conditions recognized in this trial
Adenoma
Colorectal Neoplasms
Endometrial Neoplasms
Fallopian Tube Neoplasms
Ovarian Neoplasms
Prostatic Neoplasms
Uterine Cervical Neoplasms
Vaginal Neoplasms
Vulvar Neoplasms
More general conditions related to this trial
Adnexal Diseases
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Fallopian Tube Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Genital Diseases, Female
Genital Diseases, Male
Genital Neoplasms, Female
Genital Neoplasms, Male
Gonadal Disorders
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Connective and Soft Tissue
Neoplasms, Glandular and Epithelial
Ovarian Diseases
Prostatic Diseases
Rectal Diseases
Signs and Symptoms
Signs and Symptoms, Digestive
Urogenital Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Uterine Neoplasms
Vaginal Diseases
Vulvar Diseases
Interventions listed in this trial
octreotide acetate
Additional drug interventions recognized in this trial
Octreotide
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Gastrointestinal Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
North Central Cancer Treatment Group
National Cancer Institute (NCI)
Back to top of Main Content
